Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022

Loading...
Loading...

Upgrades

  • According to Summit Insights Group, the prior rating for Applied Materials Inc AMAT was changed from Hold to Buy. For the fourth quarter, Applied Materials had an EPS of $2.03, compared to year-ago quarter EPS of $1.94. The stock has a 52-week-high of $167.06 and a 52-week-low of $71.12. At the end of the last trading period, Applied Materials closed at $104.45.
  • JP Morgan upgraded the previous rating for Walgreens Boots Alliance Inc WBA from Neutral to Overweight. For the fourth quarter, Walgreens Boots Alliance had an EPS of $0.80, compared to year-ago quarter EPS of $1.17. At the moment, the stock has a 52-week-high of $55.00 and a 52-week-low of $30.39. Walgreens Boots Alliance closed at $40.13 at the end of the last trading period.
  • For Ross Stores Inc ROST, Gordon Haskett upgraded the previous rating of Hold to Buy. In the third quarter, Ross Stores showed an EPS of $1.00, compared to $1.09 from the year-ago quarter. The stock has a 52-week-high of $115.22 and a 52-week-low of $69.24. At the end of the last trading period, Ross Stores closed at $97.93.
  • According to Northcoast Research, the prior rating for Domino's Pizza Inc DPZ was changed from Neutral to Buy. Domino's Pizza earned $2.79 in the third quarter, compared to $3.24 in the year-ago quarter. At the moment, the stock has a 52-week-high of $564.73 and a 52-week-low of $299.41. Domino's Pizza closed at $366.73 at the end of the last trading period.
  • According to UBS, the prior rating for Conagra Brands Inc CAG was changed from Neutral to Buy. For the first quarter, Conagra Brands had an EPS of $0.57, compared to year-ago quarter EPS of $0.50. The stock has a 52-week-high of $36.97 and a 52-week-low of $30.06. At the end of the last trading period, Conagra Brands closed at $34.94.

See all analyst ratings upgrades.

 

Downgrades

  • For RH RH, Wedbush downgraded the previous rating of Outperform to Neutral. In the second quarter, RH showed an EPS of $8.08, compared to $8.48 from the year-ago quarter. At the moment, the stock has a 52-week-high of $556.59 and a 52-week-low of $207.37. RH closed at $288.50 at the end of the last trading period.
  • According to B of A Securities, the prior rating for Coinbase Global Inc COIN was changed from Buy to Neutral. For the third quarter, Coinbase Global had an EPS of $2.43, compared to year-ago quarter EPS of $1.62. At the moment, the stock has a 52-week-high of $258.81 and a 52-week-low of $40.83. Coinbase Global closed at $48.79 at the end of the last trading period.
  • For HP Inc HPQ, Credit Suisse downgraded the previous rating of Outperform to Neutral. In the third quarter, HP showed an EPS of $1.04, compared to $1.00 from the year-ago quarter. The current stock performance of HP shows a 52-week-high of $41.47 and a 52-week-low of $24.07. Moreover, at the end of the last trading period, the closing price was at $29.43.
  • According to Morgan Stanley, the prior rating for Rent the Runway Inc RENT was changed from Overweight to Equal-Weight. In the second quarter, Rent the Runway showed an EPS of $0.53, compared to $3.75 from the year-ago quarter. At the moment, the stock has a 52-week-high of $8.51 and a 52-week-low of $1.37. Rent the Runway closed at $1.44 at the end of the last trading period.
  • Piper Sandler downgraded the previous rating for Chart Industries Inc GTLS from Overweight to Neutral. Chart Industries earned $1.49 in the third quarter, compared to $0.88 in the year-ago quarter. The current stock performance of Chart Industries shows a 52-week-high of $242.59 and a 52-week-low of $108.29. Moreover, at the end of the last trading period, the closing price was at $122.53.
  • Piper Sandler downgraded the previous rating for OncoCyte Corp OCX from Overweight to Neutral. At the moment, the stock has a 52-week-high of $2.26 and a 52-week-low of $0.35. OncoCyte closed at $0.43 at the end of the last trading period.
  • For Editas Medicine Inc EDIT, Oppenheimer downgraded the previous rating of Outperform to Perform. In the third quarter, Editas Medicine showed an EPS of $0.81, compared to $0.57 from the year-ago quarter. The current stock performance of Editas Medicine shows a 52-week-high of $27.99 and a 52-week-low of $9.59. Moreover, at the end of the last trading period, the closing price was at $11.01.
  • For SAP SE SAP, Jefferies downgraded the previous rating of Buy to Underperform. For the third quarter, SAP had an EPS of $1.13, compared to year-ago quarter EPS of $2.05. The current stock performance of SAP shows a 52-week-high of $141.69 and a 52-week-low of $78.22. Moreover, at the end of the last trading period, the closing price was at $111.82.
  • Credit Suisse downgraded the previous rating for Editas Medicine Inc EDIT from Outperform to Neutral. In the third quarter, Editas Medicine showed an EPS of $0.81, compared to $0.57 from the year-ago quarter. The stock has a 52-week-high of $27.99 and a 52-week-low of $9.59. At the end of the last trading period, Editas Medicine closed at $11.01.

See all analyst ratings downgrades.

 

Initiations

  • B of A Securities initiated coverage on Insmed Inc INSM with a Buy rating. The price target for Insmed is set to $39.00. Insmed earned $1.09 in the third quarter, compared to $0.96 in the year-ago quarter. The current stock performance of Insmed shows a 52-week-high of $28.94 and a 52-week-low of $16.41. Moreover, at the end of the last trading period, the closing price was at $18.53.
  • With an Outperform rating, Raymond James initiated coverage on Fulgent Genetics Inc FLGT. The price target seems to have been set at $45.00 for Fulgent Genetics. In the third quarter, Fulgent Genetics showed an EPS of $0.32, compared to $4.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $101.98 and a 52-week-low of $31.07. Fulgent Genetics closed at $35.89 at the end of the last trading period.
  • HC Wainwright & Co. initiated coverage on 4D Molecular Therapeutics Inc FDMT with a Buy rating. The price target for 4D Molecular Therapeutics is set to $36.00. In the third quarter, 4D Molecular Therapeutics showed an EPS of $0.79, compared to $0.82 from the year-ago quarter. The stock has a 52-week-high of $24.38 and a 52-week-low of $5.32. At the end of the last trading period, 4D Molecular Therapeutics closed at $22.40.
  • Piper Sandler initiated coverage on DraftKings Inc DKNG with an Overweight rating. The price target for DraftKings is set to $21.00. In the third quarter, DraftKings showed an EPS of $1.00, compared to $1.35 from the year-ago quarter. The stock has a 52-week-high of $28.55 and a 52-week-low of $9.77. At the end of the last trading period, DraftKings closed at $14.90.
  • With an Outperform rating, Credit Suisse initiated coverage on Eli Lilly and Co LLY. The price target seems to have been set at $395.00 for Eli Lilly. Eli Lilly earned $1.98 in the third quarter, compared to $1.77 in the year-ago quarter. The stock has a 52-week-high of $369.80 and a 52-week-low of $231.87. At the end of the last trading period, Eli Lilly closed at $360.77.
  • With a Neutral rating, Credit Suisse initiated coverage on Johnson & Johnson JNJ. The price target seems to have been set at $170.00 for Johnson & Johnson. For the third quarter, Johnson & Johnson had an EPS of $2.55, compared to year-ago quarter EPS of $2.60. The current stock performance of Johnson & Johnson shows a 52-week-high of $186.69 and a 52-week-low of $155.72. Moreover, at the end of the last trading period, the closing price was at $174.86.
  • Credit Suisse initiated coverage on Pfizer Inc PFE with an Outperform rating. The price target for Pfizer is set to $55.00. In the third quarter, Pfizer showed an EPS of $1.78, compared to $1.34 from the year-ago quarter. The stock has a 52-week-high of $58.55 and a 52-week-low of $41.45. At the end of the last trading period, Pfizer closed at $48.33.
  • Credit Suisse initiated coverage on AbbVie Inc ABBV with an Outperform rating. The price target for AbbVie is set to $170.00. For the third quarter, AbbVie had an EPS of $3.66, compared to year-ago quarter EPS of $2.83. The stock has a 52-week-high of $175.91 and a 52-week-low of $128.26. At the end of the last trading period, AbbVie closed at $152.16.
  • With a Neutral rating, Credit Suisse initiated coverage on Bristol-Myers Squibb Co BMY. The price target seems to have been set at $78.00 for Bristol-Myers Squibb. In the third quarter, Bristol-Myers Squibb showed an EPS of $1.99, compared to $2.00 from the year-ago quarter. The current stock performance of Bristol-Myers Squibb shows a 52-week-high of $81.17 and a 52-week-low of $60.86. Moreover, at the end of the last trading period, the closing price was at $77.16.
  • With an Underperform rating, Credit Suisse initiated coverage on Amgen Inc AMGN. The price target seems to have been set at $240.00 for Amgen. Amgen earned $4.70 in the third quarter, compared to $4.67 in the year-ago quarter. The stock has a 52-week-high of $296.67 and a 52-week-low of $214.39. At the end of the last trading period, Amgen closed at $287.30.
  • With an Outperform rating, Credit Suisse initiated coverage on Merck & Co Inc MRK. The price target seems to have been set at $120.00 for Merck & Co. For the third quarter, Merck & Co had an EPS of $1.85, compared to year-ago quarter EPS of $1.78. At the moment, the stock has a 52-week-high of $103.76 and a 52-week-low of $72.88. Merck & Co closed at $102.31 at the end of the last trading period.

See all analyst ratings initiations.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesDowngradesInitiationIntraday UpdateAnalyst RatingsBZI-Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...